Login to Your Account



Reviral's series A provides runway to move RSV candidate into the clinic

By Nuala Moran
Staff Writer

Wednesday, June 4, 2014

LONDON – UK start-up company Reviral Ltd. has attracted one of the global stars of nucleoside chemistry and antiviral drugs to its board, as it prepares the ground for a series A later this year to raise £4 million to £5 million (US$6.8 million to US$8.5 million).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription